Table 3.
Tumor Type | >2n | >3n | Total Cases |
---|---|---|---|
AML | 4.6% | 1.5% | 14,611 |
B-ALL | 25.0% | 2.0% | 3,769 |
NHL - B-Cell | 14.8% | 8.2% | 3,542 |
NHL - T-Cell | 7.2% | 5.1% | 1,497 |
Hodgkins | 48.8% | 30.3% | 244 |
T-ALL | 5.9% | 3.5% | 1,130 |
Myeloma | 39.8% | 8.3% | 1,561 |
Tumor Type | >2n | >3n | Total Cases |
---|---|---|---|
AML | 4.6% | 1.5% | 14,611 |
B-ALL | 25.0% | 2.0% | 3,769 |
NHL - B-Cell | 14.8% | 8.2% | 3,542 |
NHL - T-Cell | 7.2% | 5.1% | 1,497 |
Hodgkins | 48.8% | 30.3% | 244 |
T-ALL | 5.9% | 3.5% | 1,130 |
Myeloma | 39.8% | 8.3% | 1,561 |